Evaluation of the efficacy of Pentoxiphyllin in hospitalized diabetic patients with Covid-19

Investigating the effectiveness of pentoxifylline in diabetic patients with covid-19 : a clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190810044500N29

Enrollment

Registered

2024-10-12

Start date

2023-01-11

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19,virus identified

Interventions

Intervention 1: Intervention group: In the pentoxifylline group, patients are treated with 400 mg three times a day with pentoxifylline. Intervention 2: Control group: Patients are only treated with

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diabetic patient with covid-19 hospitalized in non-specialized departments of teaching hospitals of Yazd University of Medical Sciences

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
IL6 marker level in serum. Timepoint: Weekly. Method of measurement: Blood test.;ESR marker level in serum. Timepoint: Weekly. Method of measurement: Blood test.;CRP marker level in serum. Timepoint: Weekly. Method of measurement: Blood test.;Ferritin marker level in serum. Timepoint: weekly. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh saghafi

Yazd University of Medical Sciences

sahafi.fa@gmail.com+98 35 3820 3419

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026